Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07MGC
|
|||
| Drug Name |
Talacotuzumab
|
|||
| Synonyms |
JNJ 473; JNJ 56022473; TAL
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1], [2] | |
| Company |
Janssen Research & Development Raritan, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 3 receptor alpha (IL3RA) | Target Info | . | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Apoptosis | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL3 Signaling Pathway | ||||
| Pathway Interaction Database | IL3-mediated signaling events | |||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-3 Signaling Pathway | |||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.